Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) is included among the many 13 Corporations that Simply Began Paying Dividends.
Throughout the This fall 2025 earnings name, CEO Leonard Schleifer stated Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) delivered regular income progress. Fourth-quarter gross sales rose 3% from a 12 months earlier. He stated the rise got here from double-digit progress throughout three key merchandise.
World web gross sales of DUPIXENT climbed 32%. LIBTAYO gross sales elevated 13% on a constant-currency foundation. Within the U.S., EYLEA HD stood out, with gross sales up 66%. Schleifer pointed to that efficiency as a transparent signal of momentum, notably within the home market.
He described DUPIXENT as a core pillar of the enterprise. The drug is now utilized by greater than 1.4 million sufferers worldwide and stays positioned for additional progress. Schleifer additionally highlighted progress at LIBTAYO, citing power in adjuvant CSCC and rising share in superior non-small cell lung most cancers. Within the U.S., he stated the remedy has turn out to be the second most prescribed immunotherapy within the first-line setting.
Wanting forward, Schleifer laid out a busy regulatory and growth agenda. He stated the corporate expects at the least 4 FDA approvals, together with three new molecular entities throughout completely different modalities, together with approval of the EYLEA HD prefilled syringe.
He additionally famous plans to launch 18 extra Section III research over the approaching years, with whole enrollment of about 35,000 sufferers. In response to Schleifer, the size of funding is meant to assist the subsequent wave of potential blockbuster merchandise.
Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) is a completely built-in biotechnology firm that invents, develops, manufactures, and commercializes medicines for individuals with critical illnesses.
Whereas we acknowledge the potential of REGN as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back threat. In the event you’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 13 Greatest February Dividend Shares To Purchase and 14 Excessive Yield Dividend Shares with Sustainable Payouts
Disclosure: None.
